BackSwedish Orphan Biovitrum AB (publ) Overview

Swedish Orphan Biovitrum AB (publ) Total Current Liabilities

Track Swedish Orphan Biovitrum AB (publ)'s total current liabilities ($20B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$20.27B
↑ 44.98% YoYΔ $6.29B vs prior year quarter

Peer trimmed avg / median

Loading

Swedish Orphan Biovitrum AB (publ) Total Current Liabilities History

Loading

Swedish Orphan Biovitrum AB (publ) vs. peers: Total Current Liabilities Comparison

Loading

Swedish Orphan Biovitrum AB (publ) Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Swedish Orphan Biovitrum AB (publ) (BIOVF) FAQ

Swedish Orphan Biovitrum AB (publ) (BIOVF) currently reports a total current liabilities of $20B as of September 2026. That compares with $14B in the prior-year period — up 45.0% year over year. Use the charts on this page to explore Swedish Orphan Biovitrum AB (publ)'s total current liabilities history and peer comparisons.

Swedish Orphan Biovitrum AB (publ)'s total current liabilities increased from $14B to $20B — a 45.0% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Swedish Orphan Biovitrum AB (publ) reported $20B in total current liabilities as of September 2026. That compares with $14B in the prior-year period — up 45.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $20B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Swedish Orphan Biovitrum AB (publ), and consider following BIOVF for alerts when major investors trade the stock.

Questions & Answers